|
The FINANCIAL -- Pfizer Inc. announced that the Arthritis Advisory Committee to the U.S. Food and Drug Administration (FDA) voted 8-2 to recommend approval of the investigational agent tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). |
|
| Read more... | |
|
|
|
|
|
|


